22,414 Shares in Enovis Co. (NYSE:ENOV) Acquired by Leisure Capital Management

Leisure Capital Management acquired a new stake in shares of Enovis Co. (NYSE:ENOV - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 22,414 shares of the company's stock, valued at approximately $984,000.

Several other institutional investors have also modified their holdings of the business. DAVENPORT & Co LLC lifted its holdings in shares of Enovis by 6.0% during the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock valued at $121,181,000 after purchasing an additional 157,216 shares in the last quarter. Hantz Financial Services Inc. raised its position in Enovis by 10.3% in the 4th quarter. Hantz Financial Services Inc. now owns 247,469 shares of the company's stock valued at $10,859,000 after buying an additional 23,073 shares during the last quarter. Tributary Capital Management LLC raised its position in Enovis by 33.9% in the 4th quarter. Tributary Capital Management LLC now owns 566,089 shares of the company's stock valued at $24,840,000 after buying an additional 143,258 shares during the last quarter. Dynamic Advisor Solutions LLC raised its position in Enovis by 7.8% in the 4th quarter. Dynamic Advisor Solutions LLC now owns 18,999 shares of the company's stock valued at $834,000 after buying an additional 1,377 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its position in Enovis by 198.9% in the 4th quarter. Janney Montgomery Scott LLC now owns 20,416 shares of the company's stock valued at $896,000 after buying an additional 13,586 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a "buy" rating and issued a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $65.86.

Enovis Stock Down 5.0 %

Shares of NYSE:ENOV traded down $2.34 during trading on Thursday, hitting $44.77. 890,827 shares of the company were exchanged, compared to its average volume of 1,145,443. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -20.44 and a beta of 1.94. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The firm has a fifty day moving average price of $45.98 and a two-hundred day moving average price of $44.51. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.11. The firm had revenue of $505.22 million for the quarter, compared to analyst estimates of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business's quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.56 EPS. As a group, research analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.